ClinicalTrials.gg
CompletedNCT07511010Updated Nov 5, 2026

Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets

A Phase 1 interventional study of Chiglitazar/Metformin extended-release tablets under fasting conditions and Chiglitazar/Metformin extended-release tablets after a high-fat meal in T2DM (Type 2 Diabetes Mellitus), sponsored by Chipscreen Biosciences, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 1, Interventional, and Treatment

Updated Nov 5, 2026Now CompletedFirst site in China+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
685th of 767
28 · median 199
Started
2026
with 87 others
Phase 1
122 of 909
12 open now
Registered
819th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 685th largest by enrollment of the 767 interventional ones that give a count, is one of 88 that started in 2026, is one of 122 in phase 1, and was the 819th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

This trial includes two parts: a food effect (FE) study and a multiple-dose pharmacokinetic (PK) study.

The FE study is a randomized, open-label, two-period, two-sequence crossover study designed to evaluate the effect of a high-fat meal on the PK of a single oral dose of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants.

The multiple-dose PK study is an open-label study designed to evaluate the PK characteristics of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants following multiple oral doses.

03

Conditions studied

  • T2DM (Type 2 Diabetes Mellitus)
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female participants;
  • Age from 18 to 45 years, inclusive;
  • (BMI) between 19.0 and 26.0 kg/m² (inclusive). Male participants must weigh at least 50.0 kg, and female participants must weigh at least 45.0 kg;
  • From the time of signing the form until 3 months after the last dose, participants must have no plans for pregnancy or sperm donation and must be willing to use effective measures;
  • Voluntarily agrees to participate in the study and signs the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Any abnormalities in laboratory tests or a history of clinically significant diseases, including but not limited to cardiovascular, cerebrovascular, hepatic, renal, respiratory, gastrointestinal, neurological, hematological, immune, oncological, psychiatric, or endocrine/metabolic disorders;
  • Known history of severe allergies (e.g., allergy to more than 3 allergens, allergies affecting the lower respiratory tract such as allergic asthma, allergies requiring treatment) or a known history of allergy to any component of the products;
  • Previous surgery that could affect drug absorption, distribution, metabolism, or excretion (e.g., subtotal gastrectomy), or a history of gastrointestinal, hepatic, or renal disease within the last 6 months that could affect drug absorption or metabolism;
  • Surgery within 3 months prior to screening or planned surgery during the study period;
  • Received any vaccination within 1 month prior to screening or plan to receive any vaccination during the study period;
  • History of infectious disease treated with significant use of antibiotics within 3 months before the first dose, or any infectious disease within 7 days before the first dose;
  • Presence of gastrointestinal symptoms (e.g., diarrhea, constipation, nausea, vomiting) within 7 days before the first dose, which the investigator deems unsuitable for study participation;
  • Use of any prescription drugs, over-the-counter drugs, or Chinese herbal medicines within 1 month before the first dose; or use of vitamin products within 2 weeks before enrollment;
  • History of drug or substance abuse, or a positive alcohol or urine drug screening test;
  • Intolerance to venipuncture, or a history of fainting in response to needles or blood;
  • Fasting blood glucose > 6.1 mmol/L or \< 3.9 mmol/L at screening, and/or a history of hypoglycemia/syncope;
  • Participation in any interventional clinical trial within 3 months prior to screening;
  • Blood donation or significant blood loss (> 200 mL) within 3 months prior to screening;
  • Pregnant or lactating women;
  • Weekly alcohol consumption of more than 14 units within 3 months prior to screening, consumption of alcohol within 48 hours before the first dose, or inability to abstain from alcohol during the study;
  • Smokes more than 5 cigarettes per day within 3 months prior to screening, has smoked within 48 hours before the first dose, or is unable to abstain from smoking during the study;
  • Excessive daily consumption of tea, coffee, and/or caffeinated beverages within 3 months prior to screening, or consumption of such beverages within 48 hours before the first dose;
  • Consumption of grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), star fruit, papaya, pomegranate, or their products within 14 days before the first dose;
  • (GFR) \< 90 mL/min/1.73 m²;
  • Systolic blood pressure \< 90 mmHg or ≥ 140 mmHg, or diastolic blood pressure \< 50 mmHg or ≥ 90 mmHg at screening;
  • Inability to comply with the standardized diet (e.g., intolerance to the high-fat meal, lactose intolerance) or has difficulty swallowing;
  • Plans to or is required to engage in strenuous physical activity or exercise during the study period;
  • Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Sequence 1 of FE study

    Drug: Chiglitazar/Metformin extended-release tablets under fasting conditions · Drug: Chiglitazar/Metformin extended-release tablets after a high-fat meal

  • Experimental
    Sequence 2 of FE study

    Drug: Chiglitazar/Metformin extended-release tablets under fasting conditions · Drug: Chiglitazar/Metformin extended-release tablets after a high-fat meal

  • Experimental
    multiple-dose group

    Drug: multiple-dose of Chiglitazar/Metformin extended-release tablets

Interventions

  • DrugChiglitazar/Metformin extended-release tablets under fasting conditions

    a single dose of Chiglitazar/Metformin extended-release tablets under fasting conditions

  • DrugChiglitazar/Metformin extended-release tablets after a high-fat meal

    a single dose of Chiglitazar/Metformin extended-release tablets after a high-fat meal

  • Drugmultiple-dose of Chiglitazar/Metformin extended-release tablets

    a single dose on Day 1, once-daily consecutive doses from Day 4 to Day 10

06

What researchers measure

Primary outcomes

  1. FE Study: Maximum plasma concentration (Cmax)

    Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours

  2. FE Study: Area Under the Plasma Concentration-Time Curve (AUC)

    Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours

  3. FE Study: Time to Maximum Plasma Concentration(Tmax)

    Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours

  4. FE Study: Elimination Half-life (t1/2)

    Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours

  5. FE Study: Apparent Total Clearance (CL/F)

    Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours

  6. FE Study: Apparent Volume of Distribution during the terminal phase (Vz/F)

    Time frame: Pre-dose and at multiple timepoints post-dose up to 72 hours

  7. Multiple-dose PK study: Maximum plasma concentration (Cmax)

    Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)

  8. Multiple-dose PK Study: Area Under the Plasma Concentration-Time Curve (AUC)

    Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)

  9. Multiple-dose PK Study: Time to Maximum Plasma Concentration(Tmax)

    Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)

  10. Multiple-dose PK Study: steady-state peak concentration (Cmax,ss)

    Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)

  11. Multiple-dose PK Study: steady-state time to peak concentration (Tmax,ss)

    Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)

  12. Multiple-dose PK Study: under the plasma concentration-time curve at steady state (AUCss)

    Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)

  13. Multiple-dose PK Study: trough concentration (Ctrough)

    Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)

  14. Multiple-dose PK Study: accumulation ratio (Rac)

    Time frame: predose to 72 hours after the last dose (7 consecutive days of dosing)

Secondary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: up to Day 16

  2. Change from baseline in hematology parameters: white blood cell count, neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count, red blood cell count , hemoglobin, hematocrit, platelet count

    Change from baseline in hematology parameters: white blood cell count (WBC), neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count, red blood cell count (RBC), hemoglobin (Hb), hematocrit (HCT), platelet count (PLT)

    Time frame: up to Day 13

  3. Changes from baseline in serum chemistry parameters

    Changes from baseline in serum chemistry parameters: fasting blood glucose (FBG), total protein, albumin, total bilirubin, direct bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), blood urea nitrogen (BUN) or urea, uric acid, creatinine, potassium (K⁺), sodium (Na⁺), chloride (Cl-), creatine kinase (CK)

    Time frame: up to Day 13

  4. Changes from baseline in urinalysis parameters: urine protein, urine ketones, urine glucose, urine pH, urine leukocytes, urine red blood cells

    Changes from baseline in urinalysis parameters: urine protein, urine ketones, urine glucose, urine pH, urine leukocytes, urine red blood cells (RBCs)

    Time frame: up to Day 13

07

Study locations

1 site
  • Beijing Ditan Hospital, Capital Medical University
    Beijing, Beijing Municipality 101300, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2026 to primary completion in Oct 2026, 1 month.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 1 month is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Apr 6, 2026
StartActual
Sep 10, 2026was Oct 2026
Primary completionActual
Oct 22, 2026
CompletionActual
Oct 25, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 5, 2026
Sites
1 site added — first site in China
Show site
  • Beijing Ditan Hospital, Capital Medical University · Beijing, China
Nov 5, 2026
Start date
Oct 8, 2026→Sep 10, 2026 (actual)
Nov 5, 2026
Primary completion
Oct 26, 2026→Oct 22, 2026 (actual)
Nov 5, 2026
Study completion
Oct 26, 2026→Oct 25, 2026 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Completed
    1 site added — first site in China
    Show site
    • Beijing Ditan Hospital, Capital Medical University · Beijing, China
    Start date Oct 8, 2026→Sep 10, 2026 (now actual)
    Primary completion Oct 26, 2026→Oct 22, 2026 (now actual)
    Study completion Oct 26, 2026→Oct 25, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07511010
Responsible party
Sponsor
First posted
Apr 6, 2026
Start date
Sep 10, 2026
Primary completion
Oct 22, 2026
Completion
Oct 25, 2026
Last update
Nov 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion